387 related articles for article (PubMed ID: 29141831)
21. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
22. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Bovis F; Kalincik T; Lublin F; Cutter G; Malpas C; Horakova D; Havrdova EK; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Izquierdo G; Eichau S; Patti F; Terzi M; Grammond P; Bergamaschi R; Sola P; Ferraro D; Ozakbas S; Iuliano G; Boz C; Hupperts R; Grand'Maison F; Oreja-Guevara C; van Pesch V; Cartechini E; Petersen T; Altintas A; Soysal A; Ramo-Tello C; McCombe P; Turkoglu R; Butzkueven H; Wolinsky JS; Solaro C; Sormani MP
Neurology; 2021 Jan; 96(2):e214-e227. PubMed ID: 33024022
[TBL] [Abstract][Full Text] [Related]
23. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
24. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
25. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
[TBL] [Abstract][Full Text] [Related]
26. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.
Bellmann-Strobl J; Paul F; Wuerfel J; Dörr J; Infante-Duarte C; Heidrich E; Körtgen B; Brandt A; Pfüller C; Radbruch H; Rust R; Siffrin V; Aktas O; Heesen C; Faiss J; Hoffmann F; Lorenz M; Zimmermann B; Groppa S; Wernecke KD; Zipp F
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33762428
[TBL] [Abstract][Full Text] [Related]
29. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
30. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
31. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
32. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
34. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
35. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
36. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
37. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.
Caon C; Din M; Ching W; Tselis A; Lisak R; Khan O
Eur J Neurol; 2006 May; 13(5):471-4. PubMed ID: 16722971
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
[TBL] [Abstract][Full Text] [Related]
39. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
Carter NJ; Keating GM
Drugs; 2010 Aug; 70(12):1545-77. PubMed ID: 20687620
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
